Description

With the climatic and environmental changes, seasonal asthma has become the main reason for respiratory ailments. According to an epidemiological survey, the incidence of respiratory ailments is 16% of the incidence of all diseases. About 280 million people in the world suffer from different degrees of seasonal asthma. The situation is more serious in industrialized countries and regions where tobacco consumption is high with 5% of adults and 20% of children there having been attacked by this disease. Nearly 300 million people in China contract respiratory ailments, among which over 50 million suffer from cough with an annual growth rate of 4% and 15-20 million asthma.

View Full Report at: http://www.marketresearchreports.biz/analysis/289115

Doxofylline, a derivative of theophylline, is a methylxanthine anti-bronchospasm drug for the treatment of bronchial asthma, panting chronic bronchitis and breathing difficulties caused by other bronchospasm. It is also a common drug for acute and chronic obstructive airway disorders. Unlike other methylxanthines, dexofylline has no side effects on gastrointestinal tract, nervous system, heart and kidney. First developed and marketed by ITALY and ABC company in 1988, doxofylline has now become the best-selling drug in many countries like the US, Japan, Ireland and Canada. Chinese enterprises begun manufacturing improvements in 1992 and has now developed such dosage forms as syrup, tablet, injection and APIs. Compared with traditional theophylline and aminophylline, doxofylline has better efficacy and less toxicity and therefore is worthwhile for spreading in clinical practice.

Doxofylline develops fast after entering China, annual sales value rising from CNY 124 million in 2010 to CNY 224 million in 2014 and CAGR reaching up to 15.9% during the period of 2010-2014. Doxofylline enjoys a vast demand in China. Currently, Fuhe Huaxing Pharmaceutical Shares Co., Ltd, Xi’an Bosen BioPharma Co., Ltd, Zhejiang Hansheng Pharmaceutical Co., Ltd of Beisheng Pharma, Kaifeng Canon Pharmaceutical Co., Ltd and ReYoung Pharmaceutical Co., Ltd all take up certain shares in the market, among which Fuhe Huaxing Pharmaceutical Shares Co., Ltd has the largest market share of 27.8% with sales value in 2014 reaching up to CNY 62.33 million.

Download Detail Report With Complete TOC at: http://www.marketresearchreports.biz/sample/sample/289115

As environmental pollution worsens in China, the incidence of respiratory ailments will keep growing. Therefore, the market size of doxofylline in China is expected to keep expand in the next few years.

Readers can get at least the following information from this report:

market size of doxofylline in China
market share of manufacturers of doxofylline in China
price of doxofylline in Chinese market
major manufacturers of doxofylline in Chinese market
market outlook of doxofylline in China

The author suggests the following groups of people purchase this report:

manufacturers of respiratory drugs
investors/ research institutions interested in Chinese medicine market
any interest in the Chinese medicine market, please contact CRI for customized survey service


Browse all latest Articles of Market Research Reports
at:http://www.marketresearchreports.biz/articles

About us

MarketResearchReports.biz is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time and money for our clients.
We are a one stop solution for all your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting services. We serve all sizes and types
of companies spanning across various industries.

Browse Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz

Browse More PressRelease:
http://www.prweb.com/search.aspx?search-releases=marketresearchreports.biz


Contact
Mr. Nachiket
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA: Canada Toll Free: 866-997-4948
Website: http://www.marketresearchreports.biz/
E: [email protected]